SECsense Logo

AstraZeneca PLC's 6-K Report: Capital Group Boosts Voting Rights to 5.01%

$AZN
Form 6-K
Filed on: 2025-08-15
Source
AstraZeneca PLC's 6-K Report: Capital Group Boosts Voting Rights to 5.01%

Key Information and Insights from the Financial Report

  1. Form Type and Filing Details:
  • Form: 6-K
  • Commission File Number: 001-11960
  • Filing Date: August 15, 2025
  1. Company Information:
  • Company Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom
  • ISIN: GB0009895292
  1. Reporting Entity:
  • Notifying Entity: The Capital Group Companies, Inc.
  • Location: Los Angeles, USA
  1. Reason for Notification:
  • The notification is due to an acquisition or disposal of voting rights.
  1. Details of Holdings:
  • Threshold Crossed Date: August 13, 2025
  • Notified Date: August 14, 2025
  • Total Voting Rights Held: 77,682,857 shares
  • % of Total Voting Rights Held: 5.009591%
  • Previous Notification %: 4.984560%
  1. Breakdown of Voting Rights:
  • Voting Rights Attached to Shares:
    • Common Stock (GB0009895292): 63,331,515 shares (4.084106%)
    • Depository Receipts (US0463531089): 14,351,342 shares (0.925485%)
  • Total Voting Rights:
    • Direct Voting Rights: 77,682,857
    • Indirect Voting Rights: 0
    • Percentage of Voting Rights through Financial Instruments: 0
  1. Chain of Control:
  • The Capital Group Companies, Inc. is the parent company, overseeing several investment management entities including Capital Research and Management Company and Capital Group Private Client Services, Inc.
  1. Additional Notes:
  • The shares reported are managed under discretionary accounts by the investment management divisions of the Capital Group.
  • The report specifies that neither the Capital Group Companies nor its affiliates own shares for their own accounts.

Insights:

  • The notification signifies a significant increase in voting rights held by The Capital Group Companies, indicating a growing influence over AstraZeneca PLC.
  • The increase from 4.984560% to 5.009591% suggests strategic investment behavior, potentially aligning with AstraZeneca's long-term performance outlook.
  • Monitoring such filings can provide insights into shareholder dynamics and potential influences on corporate governance decisions at AstraZeneca.